FRANKFURT (Reuters) -Swiss drugmaker Roche has abandoned global targets for a more diverse workforce to avoid penalties from ...

By Paul Arnold, Maggie Fick ZURICH (Reuters) -Swiss drugmaker Roche has abandoned global diverse workforce targets and ...

Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...

Oxford BioTherapeutics has partnered with Roche to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer.

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

Meanwhile, fellow Swiss company Novartis will no longer use diverse panels in its hiring process for U.S.-based employees, ...

Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...

The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...

Angesichts des Drucks der Trump-Regierung hat der Schweizer Pharmariese Roche seine seit langem bestehenden globalen ...

Roche Holding (ROCH:CA) now has a Canadian dollar hedged Canadian Depositary Receipt, but it currently lacks liquidity. Read ...

The Food and Drug Administration said several lots of six products containing benzoyl peroxide are being recalled, including ...

Parent company La Roche-Posay has pulled the Effaclar Duo Acne Spot Treatment from L'Oreal's lineup, due to a cancer-causing ...